Xiang Zhang
Address:
1941 East Road,
Houston,
TX 77054,
United States.
Research Interests:
- One set of his studies focuses on oxidative stress in schizophrenia. An ancillary theme is research on the association of free radical metabolism and the pathophysiology of tardive dyskinesia (TD), a movement disorder commonly occurs in patients treated chronically with antipsychotic drugs.
- Dr Zhang's interest in this area has led to studies that underlined the importance of the antioxidant in the outcome of schizophrenia, as well as TD treatment.
- A second set of studies lie in the role of viruses and other infectious agents, together with immune dysfunction as possible causes of schizophrenia.
- A third research interest focuses on genetics and pharmacogenetics of psychiatric illness, mainly schizophrenia and antipsychotic-induced side effects, such as tardive dyskinesia, weight gain/obesity and diabetes.
- A fourth set of studies utilizes a translational approach to understand addiction vulnerability in patients with serious mental disorders mainly schizophrenia. His main focus has been on tobacco addiction co-morbidity.
Biography:
Current address: Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, 1941 East Road, Houston, TX 77054, USA, Tel: 713-791-1414 ext. 5824; 832-472-8148 (cell), Fax:713-794-7938, E-mail: [email protected], Place of Birth: Guoyang, Anhui Province, CHINA,
Education:
Ph.D. Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,
Beijing, CHINA. Sep 1995-July 1998
M.S. Psychopharmacology, Institute of Mental Health, Peking University School of Medicine,
Beijing, CHINA. Sep 1992-July 1995
M.D. Anhui Medical University, HeFei, Anhui, CHINA. Sep 1984- July 1989
Positions:
July 2009-Present Associate Professor, Department of Psychiatry and Behavioral Sciences,
Baylor College of Medicine
July 2006-June 2009 Assistant Professor, Department of Psychiatry and Behavioral Sciences,
Baylor College of Medicine
July 2003-June 2006 Associate Research Scientist, Department of Psychiatry,
Yale University School of Medicine, Connecticut, USA
Aug 2000-June 2003 Postdoctoral Fellow, Department of Psychiatry,
Yale University School of Medicine, Connecticut, USA
Aug 1999-July 2000 Postdoctoral Fellow, Center for Molecular and Behavioral Neuroscience
Rutgers University, New Jersey, USA
Aug 1998-July 1999 Research Fellow, Institute of Mental Health,
Peking University School of Medicine, Beijing, China
Aug 1994-July 1998 Attending Psychiatrist, Beijing Hui-Long-Guan Psychiatric Hospital,
Beijing, China
Aug 1989-July 1994 Resident in Psychiatry, Beijing Hui-Long-Guan Psychiatric Hospital,
Beijing, China
Academic Review Experience:
National Grant Reviewer:
The United States – Israel Binational Science Foundation (BSF) 2012
International Grant Reviewer:
National Program on Key Basic Research Project of China 2013
National Program on Key Basic Research Project of China 2012
Changjiang Scholars Programme of China 2012
Neurosciences and Mental Health Board, UK 2010
National Program on Key Basic Research Project of China 2010
Changjiang Scholars Programme of China 2010
Member of the Grant Review Board, Food and Health Bureau, Hong Kong 2012
Editorial Board:
Plos ONE 2010-present
Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009-present
Gust editor, Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012
Neuropsychopharmacology Open Journal 2009-2012
Journal of Addiction & Prevention 2013-present
Hindawi ISRN Psychiatry 2013-present
Psychology and Behavioral Sciences 2013-present
Journal Reviewer (Ad hoc): 2006-present
Acta Pharmacologica Sinica, ACTA Psychiatric Scandinavica, Addiction, Addictive biology, AIDS and Behavior, American Journal of Drug Addiction, American Journal of Drug and Alcohol Abuse, American Journal of Medical Genetics Part B, American Journal of Psychiatry, Antioxidants and Redox Signaling, Archives of General Psychiatry, Behavioral Psychopharmacology, Biological Psychiatry, Bipolar Disorders, Brain Research, Cytokines, European Journal of Neuropsychopharmacology, Human Psychopharmacology, Indian Journal of Psychiatry, Journal of Clinical Psychiatry, Journal of Nutritional Biochemistry, Journal of Psychiatric Research, Journal of Psychopharmacology, Journal of Public Health, Journal of Traumatic Stress, Molecular Psychiatry, Neuropsychopharmacology, Neuroscience Letters, Pharmacology, Biochemistry and Behavior, Plos One, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Psychiatry Research, Psychopharmacology, Schizophrenia Bulletin, Schizophrenia Research, The Lancet.
Funding:
Current Support:
National Natural Science Foundation of China (81371477) 2014-2017
“Tropisetron for cognitive function and P50 in chronic schizophreniaâ€Â
Role: Principal Investigator
2013 NARSAD Independent Investigator Grant (#20314) 2013-2015
“Tropisetron for clinical symptom and cognitive biomarkers in schizophrenia:
association with alpha 7 nicotinic receptor gene polymorphismsâ€Â
Role: Principal Investigator
Beijing Municipal Natural Science Foundation (#7132063) 2013-2016
“The pharmacogenetic mechanisms of antipsychotic-induced weight gain and obesity†Role: Principal Investigator
National Institute of Drug Abuse, 7P50DA018197 2009-2014
“Stimulant pharmacotherapy: Noradrenergic Targetsâ€Â
Role: Core-PI
- Dr Zhang has a broad background in psychiatry, with specific training and expertise in clinical psychopharmacology and pharmacogenetics in schizophrenia.
- As PI or co-Investigator on several previous Stanley Medical Research Institute foundation NARSAD and NIH-funded grants, Dr Zhang laid the groundwork for the proposed research by collecting large samples from the patients with schizophrenia who had been treated with atypical and typical antipsychotics, and by establishing a large research net all over China, in which 8 large psychiatric hospitals have participated for collaborative efforts, with more than 6,000 inpatients.
- In addition, Dr Zhang successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced many peer reviewed publications from each project.
- Up to date, Dr Zhang has published more than 150 papers in the international peer-review journals.
- In summary, Dr Zhang has a demonstrated record of successful and productive research projects in an area of clinical psychopharmacology and pharmacogenetic in schizophenia.